title: Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
abstract: Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Martin
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.forename: B J
authors.initials: BJ
authors.lastname: Dong
authors.forename: M
authors.initials: M
authors.lastname: Pirmohamed
authors.forename: D W
authors.initials: DW
authors.lastname: Haas
authors.forename: D L
authors.initials: DL
authors.lastname: Kroetz
mesh_terms: D000818:Animals; D015224:Dideoxynucleosides / Q000008:administration & dosage*; D005838:Genotype; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods / Q000592:standards*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D000099227:Abacavir
chemical_list: D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir